A Phase I clinical trial, NCT02980315, is examining the safety and effectiveness of EGFR-targeted CAR-T cell therapy in patients with advanced EGFR-positive solid tumors, such as HNSCC. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.